- ￥546 - 5490
- Solarbio
- 北京
- IC2580
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: 2-8℃，2 years
- 保质期：
Powder: 2-8℃，2 years
- 英文名：
CH-5132799
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
1007207-67-1
- 规格：
50mg/25mg/10mg/1mg/5mg
| 规格： | 50mg | 产品价格： | ￥5490.0 |
|---|---|---|---|
| 规格： | 25mg | 产品价格： | ￥3703.0 |
| 规格： | 10mg | 产品价格： | ￥2090.0 |
| 规格： | 1mg | 产品价格： | ￥546.0 |
| 规格： | 5mg | 产品价格： | ￥1290.0 |
是一种选择性的 I 类 PI3K 抑制剂，抑制 PI3Kα。
| 基本信息 | |
| CAS | No.1007207-67-1 |
| 英文名称 | CH-5132799 |
| 分子式 | C15H19N7O3S |
| 分子量 | 377.42 |
| 溶解性 | Soluble in DMSO ≥0.5mg/mL;Soluble in Water ＜ 1mg/mL |
| 纯度 | ≥98% |
| 外观(性状) | White to off-white Solid |
| 储存条件 | Powder: 2-8℃，2 years |
| MDL | MFCD22419020 |
| SMILES | NC1=NC=C(C2=C3C(N(S(=O)(C)=O)CC3)=NC(N4CCOCC4)=N2)C=N1 |
| 靶点 | PI3K |
| 通路 | PI3K/Akt/mTOR |
| 背景说明 | CH5132799 是一种选择性的 I 类 PI3K 抑制剂。。 |
| 生物活性 | Izorlisib (CH5132799) is a selective class I PI3K inhibitor. Izorlisib inhibits class I PI3Ks， particularly PI3Kα， with an IC50 of 14 nM.[1-2] |
| In Vitro | Izorlisib(CH5132799)is a selective class I PI3K inhibitor with potent antitumor activity against tumors harboring the PIK3CA mutations. Izorlisib selectively inhibits class I PI3Ks and PI3Kα mutants in in vitro kinase assays. Izorlisib inhibits class I PI3Ks，particularly PI3Kα，with an IC50 of 14 nM. IC50 values against class II PI3Ks(C2α and C2β)，a class III PI3K(Vps34)，and a class IV PI3K(mTOR)are more than 100-fold higher than that against PI3Kα. Interestingly，slightly lower IC50 values are observed against PI3Kα with oncogenic mutations E542K，E545K，and H1047R than against wild-type(WT)PI3Kα. In an analysis of cocrystal structure with PI3Kγ(PBD ID: 3APC)，Izorlisib is shown to interact with ATP-binding sites of the enzyme，suggesting an ATP competitive mode of inhibition. No significant inhibitory activities of Izorlisib are observed against a representative panel of 26 protein kinases，including RTKs，nonreceptor tyrosine kinases，and serine/threonine kinases. These data indicate that Izorlisib is a selective class I PI3K inhibitor，especially against PI3Kα and its mutants. Izorlisib shows superior antiproliferative activity across the 4 tumor types，with 75%(45/60)of lines having an IC50 below 1 μM and 38%(23/60)of lines having an IC50 below 0.3 μM[1]. |
| 细胞实验 | Mice bearing BT-474 tumors(n=14)are orally administered 50 mg/kg of Everolimus on a daily basis for 31 days and then randomized. After randomization，the mice are orally administered 50 mg/kg of Everolimus(n=4)and 12.5 mg/kg(n=5)，and 25 mg/kg(n=5)of Izorlisib on a daily basis for 7 days. C，the vehicle-，Everolimus，and CH5132799-treated(25 mg/kg)tumors are resected at 4 hours after terminal administration in B，lysed，and analyzed by Western blotting. Izorlisib administration leads to a remarkable regression in a dose-dependent manner of the tumors regrown after the long-term Everolimus treatment. The tumors are resected at the end of treatment and analyzed by Western blotting with respect to PI3K pathway inhibition. Izorlisib suppresses various effectors in the PI3K pathway，including Akt，FoxO1，S6K，S6，and 4E-BP1，whereas Everolimus inhibits only phosphorylation of S6K and S6，both downstream effectors of mTORC1[1]. |
| 细胞实验 | The cell lines are added to the wells of 96-well plates containing 0.076 to 10，000 nM CH5132799 and incubated at 37°C. After 4 days of incubation，Cell Counting Kit-8 solution is added and，after incubation for several more hours，absorbance at 450 nm is measured with Microplate-Reader iMark. The antiproliferative activity is calculated. The IC50 values are calculated[1]. |
| 动物实验 | Female BALB-nu/nu mice(CAnN.Cg-Foxn1/CrlCrlj nu/nu)are used. A total of 4×106 to 1.2×107 cells are suspended in 100 to 200 μL serum-free culture medium and injected subcutaneously into the right flank of the mice. Tumor size is measured by using a gauge twice per week，and tumor volume(TV)is calculated. Once the tumors reach a volume of approximately 200 to 300 mm3，animals are randomized into groups(n=4 or 5 in each group)and treatment is initiated. CH5132799 and Everolimus are orally administered once a day and Trastuzumab is intravenously injected once a week. |
| 数据来源文献 | [1]. Tanaka H， et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res， 2011， 17(10)， 3272-3281. [2]. Ohwada J， et al. Discovery and biological activity of a novel class I PI3K inhibitor， CH5132799. Bioorg Med Chem Leff， 2011， 21(6)， 1767-1772. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验亚油酸 linol（ e） ic acid CH3 （ CH2 ） 4 CH＝ CHCH2 CH=CH（ CH2 ） 7 COOH，脂肪酸的一种。为以甘油酯形态构成的亚麻仁油、棉籽油之类的干性油、半干性油的主要成分。占棉籽油、向日葵种子油、芝麻油的总脂肪酸的 40— 60％，占花生油、橄榄油的总脂肪酸的 25％左右。因为在空气中易氧化变硬，所以也称为干性酸，含干性酸多的油亦称为干性油.
CDllb 常用单克隆抗体或代号：Mol，OKM1；(Macl，CR3，整合素αM) 主要表达细胞：G，M，T， B， DC， NK，Mac[AS] 分子质量(kDa)和结构：gp170(整合素α) 功 能：iC3b和Fs受体，与ICAM-l和X因子结合，黏附，调理吞噬；结合JAM-3 CDllc 常用单克隆抗体或代号：LeuM乳(CR4．整合素αX) 主要表达细胞：M，G，B
Conjugation of 5′‐Functionalized Oligodeoxyribonucleotides with Properly Functionalized Ligands
). For halogenoalkylated ligands, R1 = Acr‐NH‐(CH2 )6 ‐ ( UNIT , structure 1e); Pso‐(CH2 )6 ‐ ( UNIT , structure 2f), OP‐C(O)‐(CH2 )5 ‐ ( UNIT , structure 3c); and TO‐(CH2 )8 ‐ ( UNIT , structure 4e). For the iodoacetamidylated ligand, R2 = FLU
技术资料暂无技术资料 索取技术资料
